Scancell (LON:SCLP) Trading 5.1% Higher – Still a Buy?

Scancell Holdings plc (LON:SCLP) traded up 5.1% during trading on Friday . The company traded as high as GBX 10.50 ($0.14) and last traded at GBX 10.25 ($0.14). 9,863,690 shares were traded during trading, an increase of 953% from the average session volume of 936,871 shares. The stock had previously closed at GBX 9.75 ($0.13).

Scancell Stock Up 2.4%

The business’s 50-day simple moving average is GBX 9.91 and its 200 day simple moving average is GBX 9.44. The company has a current ratio of 3.42, a quick ratio of 13.01 and a debt-to-equity ratio of -566.79. The firm has a market cap of £108.70 million, a PE ratio of -16.09 and a beta of 0.35.

Insider Buying and Selling at Scancell

In other news, insider Martin Diggle purchased 44,944 shares of the stock in a transaction dated Tuesday, May 20th. The shares were purchased at an average cost of GBX 9 ($0.12) per share, with a total value of £4,044.96 ($5,368.94). 4.96% of the stock is owned by insiders.

Scancell Company Profile

Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.

Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.